[Correspondence] Carfilzomib for relapsed or refractory multiple myeloma – Authors' reply

In the randomised, phase 3 ENDEAVOR trial in patients with relapsed or refractory multiple myeloma, we showed that treatment with carfilzomib and dexamethasone compared with bortezomib and dexamethasone significantly improved progression-free survival (18 ·7 months with carfilzomib vs 9·4 months with bortezomib; hazard ratio [HR] 0·53 [95% CI 0·44–0·65]; p
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Tags: Correspondence Source Type: research